Nataliya N. Mazanova

Nataliya N. Mazanova

Auto-generated profile, based on publicly available information

Nataliya N. Mazanova

National Medical Research Center for Children’s Health

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2021 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Closed access
PDF file
KSKirill Savostyanov
Kirill Savostyanov
APAleksander Pushkov
Aleksander Pushkov
EBElena N. Basargina
Elena N. Basargina
LKLyudmila M. Kuzenkova
Lyudmila M. Kuzenkova
NMNatalia N. Mazanova
Natalia N. Mazanova
AFAndrey P. Fisenko
Andrey P. Fisenko
Introduction. Pompe disease (PD) or type II glycogenosis is a rare multisystem hereditary accumulation disease caused by a deficiency of the enzyme acid maltase (acid alpha-1,4-glucosidase), which leads to reduced activity to the accumulation of glycogen in various organs and tissues of the body. The aim of the study is to develop a high-performance method of early biochemical diagnosis of PD and optimization of its molecular genetic diagnosis. Materials and methods. The characteristics of the relative frequencies and spectrum of the detected mutations were studied using a sample of 7670 patients with suspected Pompe disease admitted to the National Medical Research Center of Children’s Health of the Ministry of Health of Russia as part of the selective screening, as well as eight patients with PD, whose laboratory diagnosis was made outside the framework of this selective screening. Results. As a result of selective screening of PD in Russian patients from high-risk groups, the detectability was 0.47%. PD’s clinical and age characteristics in both children and adults are described. The relative frequencies are calculated, and the spectrum of 47 pathogenic variants of the GAA gene responsible for the occurrence and development of Pompe disease in 44 patients is characterized. Seventeen new mutations of the GAA gene, unknown previously, have been identified and described, adding 2.7% to the HGMD database. Conclusion. Optimization of the algorithm of molecular diagnosis of Pompe disease in Russian patients is proposed.

10 October 2018 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
KSKirill Savostyanov
Kirill Savostyanov
NMN.N. Mazanova
N.N. Mazanova
APAleksander Pushkov
Aleksander Pushkov
PAPetr Ananin
Petr Ananin
ASA.V. Sukhozhenko
A.V. Sukhozhenko
LNLeyla S. Namazova-Baranova
Leyla S. Namazova-Baranova
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.

1 October 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
GMG. B. Movsisyan
G. B. Movsisyan
KSK. V. Savost`yAnov
K. V. Savost`yAnov
APAleksander Pushkov
Aleksander Pushkov
NMN. N. Mazanova
N. N. Mazanova
JKJ. V. Khazykova
J. V. Khazykova
ДХД. В. Хазыкова
Д. В. Хазыкова
The current gold standard for the treatment of Gaucher disease type 1 in children is enzyme replacement therapy. The efficacy and safety of treatment with velaglucerase alfa have been assessed in only a few large studies involving pediatric patients as subjects of research. In the Russian literature, there are no data available on the use of velaglucerase alfa in drug-naïve patients with Gaucher disease type 1. The aim of our study was to assess the efficacy and safety of treatment with velaglucerase alfa in children with Gaucher disease type 1. The study was approved by the Independent Ethics Committee and the Scientific Council of the National Medical Research Center for Children's Health of Ministry of Healthcare of the Russian Federation. All patients and/or their legal representatives gave their informed consent to the study. The efficacy of treatment with velaglucerase alfa in children with Gaucher disease type 1 was assessed by analyzing monitoring data of 15 patients aged 2 to 15 years who had been registered in the Russian Pediatric Gaucher Registry established at National Medical Research Center for Children's Health of Ministry of Healthcare of Russia over the period from 2015 to 2023. None of the patients had ever undergone enzyme replacement therapy before they were included in this study. The median age at the start of treatment was 6.5 years. We analyzed the patients' anthropometric, laboratory and instrumental data at 0, 6, 12, 24 and 36 months. The initial dose of enzyme replacement therapy ranged from 30 to 60 units/kg (with the median of 43 units/kg per infusion) once every 2 weeks based on disease severity. In as little as 6 months after the initiation of therapy with velaglucerase alfa, patients with Gaucher disease type 1 showed a statistically significant improvement in all measured parameters (p < 0.001): normalization of the median hemoglobin concentration and platelet count (from 113 to 125 g/L and from 111 to 163 × 109/L, respectively); a reduction in degree of liver and spleen enlargement (in terms of volume, from 45.1 to 17.9% and from 39.4 to 15.5%, respectively); a reduction in degree of the right liver lobe enlargement (in terms of linear measurements, from 27.2 to 11.1%); a reduction in degree of spleen enlargement (in terms of its length and width, from 73.4 to 37.8% and from 60.3 to 17.5%, respectively). Our patients had a remarkable decrease in biomarker activity after 3 years of therapy: chitotriosidase activity decreased from 2699 to 227 nmol/mL/h and glucosylsphingosine level was reduced from 204.0 to 35.3 ng/mL (р < 0.001). There were no adverse events during the course of treatment. After 6 months and 1 year of regular enzyme replacement therapy with appropriate doses of velaglucerase alfa initiated in a timely manner, children with Gaucher disease type 1 achieve normal hemoglobin concentrations and platelet counts, a reduction in biomarker activity, and a decrease in liver and spleen volumes. After 3 years of enzyme replacement therapy, patients achieve their main therapeutic goals such as the resolution of anemia and thrombocytopenia, an almost complete regression of hepatosplenomegaly and the normalization of bone mineral density and height adjusted for age.

15 April 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
GMG.B. Movsisyan
G.B. Movsisyan
ARA.A. Roppelt
A.A. Roppelt
DYD.V. Yukhacheva
D.V. Yukhacheva
ASA.Yu. Shcherbina
A.Yu. Shcherbina
NSNataliya Sergeevna Smetanina
Nataliya Sergeevna Smetanina
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Gaucher disease (GD) is an autosomal recessive disease that leads to excessive accumulation of glucocerebroside in the cells of the reticuloendothelial system, which leads to multiple organ damage with the development of cytopenia, hepatosplenomegaly, bone and neurological pathology. An effective and safe enzyme replacement therapy has been developed for the treatment of GD. However, there are rare cases of hypersensitivity reactions presented in the literature, requiring individualization of patient management with the search for alternative ways to continue therapy and prevent side effects. We present a rare clinical case of intolerance to imiglucerase and velaglucerase alfa in a child with GD type 3 and possible methods for continuing treatment, taking into account the hypersensitivity reaction.

13 December 2022 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
OKO. B. Kondakova
O. B. Kondakova
KKK. A. Kazakova
K. A. Kazakova
ALA. A. Lyalina
A. A. Lyalina
NLN. V. Lapshina
N. V. Lapshina
APA. A. Pushkov
A. A. Pushkov
KSKirill Savostyanov
Kirill Savostyanov
Aromatic L‑amino acid decarboxylase (AADC) deficiency is rare autosomal recessive neurometabolic disorder. It caused by generalized combined deficiency of serotonin, dopamine, norepinephrine and adrenaline. This disorder is characterized by muscular hypotonia, motor development delay, oculogyric crises and impairment of the autonomic nervous system.Laboratory diagnostic of AADC deficiency in Russian Federation includes determination of the concentration of 3‑O‑methyldophamine in dried blood spots by tandem mass spectrometry and molecular analysis of the DDC gene by Sanger sequencing or next generation sequencing.Therapy of AADC deficiency includes combination of drugs which increase the formation of dopamine, inhibit its reuptake and increase the residual activity of the enzyme. The first‑line drugs are selective dopamine agonists, monoamine oxidase inhibitors of type B and vitamin B6 supplements.We present the case of management and treatment of patients with AADC deficiency. The patient’s condition was improved by using of combination therapy with pyridoxal‑5‑phosphate, pramipexole and selegiline. Significant positive dynamics was achieved on pyridoxal‑5‑phosphate therapy for the first time.

30 June 2023 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
АСАнгелина Викторовна Соколова
Ангелина Викторовна Соколова
TBTatiana V. Bushueva
Tatiana V. Bushueva
LKLyudmila M. Kuzenkova
Lyudmila M. Kuzenkova
TBTatyana Е. Borovik
Tatyana Е. Borovik
OGOksana V. Globa
Oksana V. Globa
МХМариям У. Хубиева
Мариям У. Хубиева
Propionic aciduria (PA) is an autosomal recessive hereditary disease from the group of organic aciduria, caused by a deficiency of propionyl-CoA carboxylase, leading to impaired metabolism of methionine, threonine, valine, isoleucine, and fatty acids with an odd number of carbon atoms and cholesterol. The neonatal form of PA manifests itself during the first week of life, is characterized by an acute onset and a crisis course, which is accompanied by severe metabolic acidosis, hypoglycemia, hyperketonemia, hyperammonemia. Clinical symptoms are dominated by neurological disorders up to stupor or coma, which can lead to death. Since 2023, expanded neonatal screening has been introduced throughout the Russian Federation, which includes 36 groups of nosologies, as well as a number of hereditary metabolic diseases. Despite the inclusion of this pathology in expanded neonatal screening, doctors’ awareness of clinical manifestations and necessary therapy remains insufficient. Often such patients are diagnosed with, for example: hypoxic-ischemic damage to the central nervous system, acute meningoencephalitis, and others, which leads to inadequate therapy with the development of fatal neurological consequences. Therefore, the totality of knowledge and alertness of doctors regarding diseases from the group of hereditary metabolic diseases will help not only to suspect this pathology in a timely manner, but also to prescribe adequate therapy in time, which in the future will make it possible to prevent serious consequences and neurological disorders, as well as disability of patients.